Business
Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced, following approval at its 2025 Extraordinary General Shareholders' Meeting, that Foresee Pharmaceuticals USA Inc., the Company's fully-owned US subsidiary, has officially signed an exclusive global licensing agreement with Primevera Therapeutics, LLC (hereinafter referred to as "Primevera") for its MMP-12 inhibitor programs. The agreement includes FP-025, FP-020 and third-generation MMP-12 inhibitors currently in the drug discove
About this update from Foresee Pharmaceuticals Co., Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC.","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Foresee will receive a 10 million USD upfront payment, potential milestones of up to 584.5 million USD, single-digit royalties and retains a 19% equity in Primevera, ensuring participation in future value creation.","length":214,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":327,"olType":false},{"type":"text","content":"TAIPEI, Jan. 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced, following approval at its 2025 Extraordinary General Shareholders' Meeting, that Foresee Pharmaceuticals USA Inc., the Company's fully-owned US subsidiary, has officially signed an exclusive global licensing agreement with Primevera Therapeutics, LLC (hereinafter referred to as "Primevera") for its MMP-12 inhibitor programs. The agreement includes FP-025, FP-020 and third-generation MMP-12 inhibitors currently in the drug discovery stage.","length":594,"tagName":"p"},{"type":"text","content":"In return, Foresee USA will receive an upfront payment of 10 million USD, future potential milestones of up to 574.5 million USD and tiered single-digit percentage royalties. [Should Primevera sublicense its rights under the Agreement, Foresee will be entitled to a tiered percentage of all proceeds received by Primevera as part of its sublicense agreements, in lieu of the milestones and royalties]. Furthermore, Foresee USA will hold a 19% equity interest in Primevera. This transaction will have a positive and material impact on boosting Foresee's working capital and shareholder equity, while reducing R&D expenses and reinforcing financial stability, with a focus on near to mid-term profitability.","length":738,"tagName":"p"},{"type":"text","content":"This strategic move marks a transformative milestone for Foresee, enabling the company to streamline operations and prioritizes its SIF (Stabilized Injectable Formulation) portfolio. Foresee is at a pivotal junction in its growth trajectory, and intends on building its revenue stream by concentrating resources on CAMCEVI, and its FP-001, 6-month long-acting injectable which h...